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Abstract 
Bevacizumab, the recombinant antibody targeting vascular endothelial growth factor (VEGF), 
improves progression-free but not overall survival in metastatic breast cancer. To seek further 
insights in resistance mechanisms to bevacizumab at the molecular level, we developed VEGF and 
non-VEGF–driven ER-positive MCF7-derived xenograft models allowing comparison of tumor 
response at different timepoints. VEGF gene (MV165) overexpressing xenografts were initially 
sensitive to bevacizumab, but eventually acquired resistance. In contrast, parental MCF7 cells 
derived tumors were de novo insensitive to bevacizumab. Microarray analysis with qRT-PCR 
validation revealed that Follistatin (FST) and NOTCH were the top signaling pathways associated 
with resistance in VEGF-driven tumors (P<0.05). Based on the presence of VEGF, treatment with 
bevacizumab resulted in altered patterns of metagenes and PAM50 gene expression. In 
VEGF-driven model after short and long-term bevacizumab treatments, a change in the intrinsic 
subtype (luminal to myoepithelial/basal-like)  was observed in association with increased expres-
sion of genes implicated with cancer stem cell phenotype (P<0.05). Our results show that the 
presence or absence of VEGF expression affects the response to bevacizumab therapy and gene 
pathways. In particular, long-term bevacizumab treatment shifts the cancer cells to a more ag-
gressive myoepithelial/basal subtype in VEGF-expressing model, but not in non-VEGF model. 
These findings could shed light on variable results to anti-VEGF therapy in patients and emphasize 
the importance of patient stratification based on the VEGF expression. Our data strongly suggest 
consideration of patient subgroups for treatment and designing novel combinatory therapies in the 
clinical setting. 
Key words: Bevacizumab, vascular endothelial growth factor, breast cancer, estrogen receptor, de 
novo and acquired resistance. 
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Introduction 
Vascular endothelial growth factor (VEGF) is a 
well-known stimulator of tumor angiogenesis, growth 
and metastasis in breast cancer. Overexpression of 
VEGF is an early event in breast cancer progression 
and a prerequisite step to tumor invasion (e.g., in 
ductal carcinomas in situ) [1]. VEGF and its receptors 
have been identified in different breast cancer sub-
types [2-4]. Elevated expression of VEGF can be asso-
ciated with shorter relapse-free survival and overall 
survival times in breast cancer patients with both 
positive and negative lymph nodes [3, 4]. Recently, 
higher intratumor levels of VEGF have also been re-
ported in triple receptor-negative breast cancer and 
are associated with a shorter overall survival duration 
[5]. Overexpression of VEGF has also been linked to 
increased metastatic potential, resistance to chemo-
therapy and hormonal therapy [6-8]. Therefore, ther-
apeutic targeting of VEGF should have promise in 
breast cancer. 
The humanized monoclonal antibody against 
VEGF, bevacizumab ([BEV] Avastin; Genentech Inc., 
South San Francisco, CA), is the most advanced an-
ti-VEGF therapy in breast cancer. While the first phase 
III trial of BEV in refractory metastatic breast did not 
provide a benefit in combination with capecitabine 
[9], the E2100 trial demonstrated significant prolon-
gation of the median progression-free survival in 
metastatic breast cancer [10]. Additionally, this trial 
identified an association of the VEGFA-2578 AA and 
-1154 AA genotypes with better median overall sur-
vival than other genotypes [11]. Two subsequent 
phase III trials (AVADO and Ribbon-1) in the first-line 
setting also demonstrated improvements in progres-
sion-free survival [12, 13]. Although these trials met 
the primary endpoint of progression-free survival, 
they did not show an improvement in overall surviv-
al.  
One obvious limitation of these trials has been 
the lack of therapeutic individualization; i.e., stratifi-
cation of patients based on VEGF expression. Another 
note of caution issued by preclinical studies suggested 
that adjuvant anti-VEGF therapies may increase the 
risk of metastasis [14, 15], although this fact has not 
been observed in clinical settings. The mixture of 
promises and partial clinical failures prompts further 
efforts to gain a deeper understanding of the tumor 
response and adaptation to the anti-VEGF challenge 
and develop rational strategies to overcome resistance 
to such agents.  
In this study, we aimed to investigate the 
mechanisms of resistance to BEV in breast cancer. To 
this end, we developed in vivo breast cancer models 
of both short term and long term responses to BEV, 
based on a non-VEGF and VEGF-expressing MCF7 
cells. 
Here, we report distinct pathways of response to 
BEV in these models, which may provide critical in-
sights into the alteration of breast cancer biology 
during VEGF blockade. These pathways may also 
provide important clues for identifying synergistic 
therapeutic strategies to overcome or delay resistance 
to antiangiogenic agents.  
Materials and Methods 
Breast cancer cell lines 
ML20 (MCF7 cells transfected with control 
plasmid and MV165 (MCF7 cells transfected with 
VEGF) were a kind gift from Dr. F. G. Kern [16]. Both 
cell lines have been carefully maintained in a humidi-
fied tissue culture incubator at 37 oC in 5% CO2, and 
stocks of the earliest passage cells have been stored. 
The cell lines were grown in culture media containing 
supplements as described previously in the reference.  
Orthotopic xenograft models 
MV165 tumors display a better tumor engraft-
ment compared with ML20. Tumor characteristics 
have been characterized previously [17]. ML20 
(10×106) or MV165 cells (5×106) were implanted into 
the mammary fat pad of athymic nude mice as de-
scribed previously [17, 18]. Once tumors were estab-
lished, the mice were treated with the saline control 
(PBS) or BEV (5mg/kg, i.p./twice weekly). Treatment 
was continued for 3 weeks when the tumors are sen-
sitive to BEV at an early timepoint (defined as the 
group of sensitive to BEV, short-term [ST]). We con-
tinued to treat mice with vehicle, BEV, or anti-mouse 
VEGF antibody to develop resistant tumors, and 
harvested tumors when they reached the tumor bur-
den limit (2000mm3). At 8 weeks, they were harvested 
when they were progressing and insensitive to BEV 
(defined as the group of resistant, long-term [LT]). In 
addition, mice were treated with anti-mouse VEGF 
antibody (Genentech, 5mg/kg, i.p./twice weekly) for 
both early and late timepoints (n=6 per each condi-
tion). All tumors were harvested at the designated 
timepoints and snap frozen in liquid nitrogen and 
stored at –80 oC until RNA isolation. Tumor volume 
was calculated as L×W2/2, where L is length and W is 
width. All animal experiments were done under a 
protocol approved by the Indiana University Institu-
tional Animal Care and Use Committee.  
Microarray analysis 
Total RNA was extracted from snap-frozen tu-
mors using TRIzol Reagent method (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s in-
structions. The quality of RNA was assessed using the 
Nanodrop ND-1000 Spectrophotometer (ThermoSci-
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entific, Wilmington, DE). The RNA integrity number 
was measured using the Agilent Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). All RNA samples 
were treated with Turbo DNase (Ambion, Foster City, 
CA). 200ng of total RNAs from tumors sensitive to 
BEV (3 weeks; ST) or resistant to BEV (8 weeks; LT) or 
with vehicle control group were subjected to 
whole-genome gene expression analysis for both 
human WG-6v2 and mouse WG-6v2 Expression 
Beadchips (Illumina, San Diego, CA) as per manu-
facturer’s protocols (n=4 per each condition).  
Data preprocessing 
Data was analyzed for each condition in tripli-
cates from Illumina human and mouse WGGEX ar-
rays. Genes which had a poor signal quality across a 
maximal number of arrays were filtered out. As a re-
sult, 10,804 genes and 15,492 genes were found to 
have signals significantly above background for hu-
man and mouse arrays, respectively. The data was 
quantile normalized and log2 transformed before sta-
tistical analysis. We performed one-way ANOVA 
analysis to identify differentially expressed genes in 
our dataset.  
Ingenuity Pathways Analysis 
To identify the statistically significant biological 
functions, and signaling pathways affected by the 
genes differentially expressed in our comparisons, we 
performed Ingenuity Pathways Analysis (IPA; Inge-
nuity Systems, Inc). IPA is the largest curated data-
base and analysis system for understanding the sig-
naling and metabolic pathways, molecular networks, 
and biological processes that are most significantly 
changed in a dataset of interest (http://www. 
ingenuity.com).  
Validation of the selected genes by real-time 
quantitative reverse transcription PCR 
(qRT-PCR) 
All qRT-PCR reactions were performed in trip-
licates. Total RNAs were reverse-transcribed using 
high capacity cDNA reverse transcription kit. The 
mRNA levels were analyzed by real-time qRT-PCR 
using TaqMan gene expression assays on an ABI 
Prism 7900 platform according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA). 
Actin (ACTB) was used as endogenous control for 
normalization purpose. The relative quantification of 
the gene expression changes (fold) was analyzed ac-
cording to DDCt method using the Applied Biosys-
tems DataAssistTM Software v3.0. 
Immunohistochemical staining  
Tumors per condition (triplicates) were fixed 
with formalin for immunohistochemistry. Im-
munostaining procedures for keratin 5/6 (KRT5/6 or 
cytokeratin 5/6), keratin 14 (KRT14 or cytokeratin 14), 
ER, and Ki67 were performed as described previously 
[19-21]. Images were recorded using an Olympus 
BS41 microscope with DP72 camera. 
Results 
Xenografts exhibit different characteristics of 
resistance to BEV treatment based on the 
presence of VEGF expression status  
To investigate the mechanisms associated with 
resistance to BEV therapy, we first compared tumor 
response at different timepoints of BEV treatment. 
Tumor growth was supported with estrogen, as de-
scribed before [16]. Non-VEGF xenograft tumors 
(ML20) exhibited no visible decrease in growth dur-
ing VEGF blockade, suggesting de novo resistance 
(Fig. 1A). In contrast, BEV significantly reduced the 
primary tumor growth of the VEGF-overexpressing 
xenograft tumors (MV165) at 3 weeks (5mg/kg, 
i.p./twice weekly) (Fig. 1B). Despite the initial re-
sponse to BEV, MV165 tumors showed development 
of acquired resistance and progressed to the tumor 
volume of control mice after prolonged (8 weeks) 
treatment. Additional mice were treated with murine 
anti-VEGF monoclonal antibody (muMAb VEGF; 
Genentech; 5mg/kg, i.p./twice weekly) to confirm 
that the resistance was not due to murine VEGF of 
stromal origin. muMAb VEGF inhibited the tumor 
growth in MV165 xenograft tumors in a similar fash-
ion (data not shown).   
Gene expression profiles – human-specific 
arrays 
VEGF-driven MV165 and non-VEGF–driven ML20 
xenograft models 
To identify the molecular mechanisms associated 
with the acquired resistance to BEV therapy, we per-
formed gene expression analysis for VEGF-driven 
MV165 tumors treated with BEV at 3 weeks sensitive 
to therapy (ST treatment; MV165-ST) and 8 weeks 
resistant to therapy (LT treatment; MV165-LT) using 
Illumina human-specific (WG-6 v2) whole-genome 
expression arrays. Control tumors treated with vehi-
cle were also analyzed (MV165-V [vehicle]). Differen-
tially regulated genes were determined using 
ANOVA and IPA [13]. Of the 10,894 genes that were 
significantly above background, 64 and 37 genes were 
differentially regulated between MV165-LT versus 
MV165-ST and MV165-LT versus MV165-V, respec-
tively (ANOVA) (Additional File 1: Suppl. Fig. S1). 
Among the 64 genes in MV165-LT compared with 
MV165-ST, 61 genes were unique to tumor growth 
after initial BEV response, suggesting that these genes 
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mediate acquired resistance. Twenty-four genes were 
altered when BEV reduced the tumor growth signifi-
cantly at 3 weeks. Among the 24 genes, 12 genes were 
unique to MV165-ST sensitive group. Using IPA, Ta-
ble 1 illustrates the top five differentially regulated 
genes in MV165-LT and MV165-ST groups (P ≤0.05). 
Follistatin (FST), the activin/bone morphogenetic 
protein (BMP) antagonist, and HEY2, the downstream 
effector of NOTCH pathways, were among the top 
genes upregulated in acquired resistance to anti-BEV 
therapy. These results indicate that LT BEV treatment 
alters alternative biological pathways that may be 
associated with acquired tumor resistance.  
Due to the lack of therapeutic individualization 
in the clinic, we also aimed to investigate the mecha-
nisms of resistance to BEV in ML20 xenograft tumors, 
a non-VEGF and ER-positive breast cancer preclinical 
model. As expected, ML20 tumors lacking VEGF were 
insensitive to BEV even at ST treatment representing 
de novo resistance (relative primary resistance). Of 
the 10,894 genes found to have signals significantly 
above background, 40 and 67 genes were differen-
tially regulated in ML20-ST versus ML20-V and 
ML20-ST versus ML20-LT, respectively (Additional 
File 1: Suppl. Fig. S2). Of the 40 genes in ML20-ST 
compared with ML20-V, 30 genes were altered unique 
to ST BEV treatment, while 23 of 38 genes in ML20-LT 
compared with ML20-V were altered after LT treat-
ment to BEV. Comparison of LT versus ST further 
revealed that 49 genes were altered in LT rather than 
ST. Using IPA, Table 1 illustrates the top five differ-
entially regulated genes in ML20-ST and ML20-LT 
groups (P≤0.05). MUC5AC/MUC5B and HEY2 were 
among the top genes, suggesting a role for IL17 sig-
naling, and NOTCH pathways in de novo resistance to 
BEV therapy. In addition, other top pathways altered 
include G-protein coupled receptor signaling. Inter-
feron signaling is activated in ST and LT treatment 
when compared with vehicle.  
 
 
Figure 1. ML20 (non-VEGF–driven MCF7) and MV165 (VEGF-driven MCF7) xen-
ografts exhibit different patterns of response to BEV treatment at different 
timepoints. MV165 (5x106) and ML20 (10x106) cells were implanted into mammary 
fat pads of athymic mice (4 mice per group) in the presence of supplemental estrogen. 
Treatment with BEV (5mg/kg/ i.p/twice weekly) or vehicle control was started when 
tumors were palpable. A, ML20-V, ML20-ST, ML20-LT, (n=4), B, MV165-V, 
MV165-ST, MV165-LT. BEV, bevacizumab; LT, long-term; ST, short-term; V, vehicle. 
 
Table 1. Top differentially-regulated genes in MV165 and ML20 in response to short-term (ST) and long-term (LT) bevacizumab 
treatment using human arrays. 
Gene Symbol Canonical Pathway Gene Symbol Canonical Pathway 
MV165-LT versus MV165-ST ML20-LT versus ML20-ST 
FST TGFB/BMP signaling, regulator of angio-
genesis 
IF44 Interferon signaling 
HEY2 NOTCH signaling IF127 Interferon signaling 
FGD3 CDC42 signaling IFI544L Interferon signaling 
MUCL1 Bone micrometastasis PARP10 Retinoic acid mediated apoptosis signaling 
CYP26B1 RAR activation BGN BMP signaling 
MV165-LT versus MV165-V ML20-LT versus ML20-V 
HBA1/HBA2 Oxygen transport IFI44 Interferon signaling 
CYP26B1 RAR activation MUC5AC IL17A signaling in airway cells 
PCP4 B cell tolerance IFI27 Interferon signaling 
AOX1 NRF2-mediated  oxidative stress response, 
amino acid metabolisms PARP10 
Retinoic acid mediated apoptosis signaling 
APOD RAR activation HEY2 NOTCH signaling 
MV165-ST versus MV165-V ML20-ST versus ML20-V 
HBA1/HBA2 Oxygen transport MUC5AC/MUC5B IL17A signaling in airway cells 
AGR3 Steroid hormones regulation HEY2 NOTCH signaling  
APOD RAR activation GALR2 G-protein coupled receptor signaling 
AOX1 NRF2-mediated oxidative stress response, 
amino acid metabolisms 
AGTR1 G-protein coupled receptor signaling 
AGR2 Steroid hormones regulation ARL4A IL17A signaling in airway cells 
* ANOVA and Ingenuity Pathway Analysis have been performed; P≤0.05 
†Fold change ≥1.5 or ≤–1.5 
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Real-time qRT-PCR validation of the 
differential expression for the selected genes in 
response to ST and LT treatment to BEV 
The top differentially expressed genes in 
VEGF-driven model associated with acquired re-
sistance to BEV were validated by qRT-PCR. The ex-
pression of FST was decreased 3-fold in the sensitive 
group and was increased 2.90-fold in the resistant 
VEGF-driven MV165 group compared with vehicle 
confirming the expression levels observed in micro-
array analysis (Fig. 2). BEV altered the mRNA ex-
pression levels of FST in an inverse manner; namely 
upregulating it in resistance group and downregu-
lating it in sensitive group. We next assessed two 
members of NOTCH signaling, NOTCH3 and 
NOTCH4 receptors, whose altered expression levels 
have been implicated in the commitment of bipotent 
progenitors to the luminal lineage in normal human 
mammary development [22]. NOTCH4 levels were 
elevated in both sensitive and resistant groups to BEV 
(2.48-fold and 5-fold, respectively), but was statisti-
cally significant only in the resistant group (P<0.05). 
NOTCH3 expression was similar in these groups. In 
contrast to FST expression, levels of NOTCH4 were 
gradually increased, resulting in a significant upreg-
ulation in resistant group. In contrast, BEV treatment 
did not alter the gene levels in the same manner in 
ML20 (non-VEGF) model. There was a trend that the 
levels of FST and NOTCH4 were elevated in the LT, 
but these results did not reach the statistical signifi-
cance as in MV165 (VEGF-driven) model, supporting 
the differential regulation of top 
pathways (FST, NOTCH3, and 
NOTCH4) between two models. 
Comparison of gene 
expression profiles of ST and 
LT treatment of BEV with the 
eight metagenes in 
VEGF-drive and 
non-VEGF–driven breast 
cancer models 
To assess the impact of short 
term and sustained BEV treatment 
on clinically relevant pathways, we 
investigated gene expression in 
eight metagenes of significant rel-
evance for breast cancer [23]. 
Comparison of the selected meta-
genes demonstrated that BEV pro-
foundly decreased the genes in the 
proliferation metagene in MV165 
xenografts (Fig. 3A). However, 
most of the basal cytokeratins in 
basal-like metagene were upregu-
lated in response to BEV regardless 
of treatment duration. Compari-
sons of ML20 (non-VEGF model) 
gene profiling with metagenes re-
vealed distinct differences between 
ML20 and MV165 in response to 
BEV treatment (Figs. 3A, 3B). Un-
like the MV165 model, BEV upreg-
ulated some of the proliferation 
genes in ML20 model (Fig. 3B). 
 
 
 
 
 
 
Figure 2. Validation of selected genes using quantitative real-time RT-PCR. Fold change for each comparison was 
calculated using DataAssist Software (Applied Biosystems, Foster City, CA). Data is normalized to a reference gene 
(ACTB). P<0.05 is considered significant. ML20 (non-VEGF) and MV165 (VEGF-expressing); *P<0.05 statistically 
significant. LT, long-term; ST, short-term; V, vehicle. 
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Figure 3. Comparison of gene expression profiles of short-term (ST) and long-term (LT) treatment of bevacizumab with the eight metagenes in VEGF-driven and 
non-VEGF–driven breast cancer models. Heatmap representation of differentially regulated genes in comparison to eight metagenes A, MV165-ST and MV165-LT normalized to 
vehicle, B, ML20-ST and ML20-LT normalized to vehicle, C, comparison of MV165-ST and MV165-LT normalized to vehicle to hypoxia metagene, D, comparison of ML20-ST and 
ML20-LT normalized to vehicle to hypoxia metagene. 
 
We also compared the effect of BEV on other 
metagenes representative of adaptive responses to the 
tumor microenvironment. Of the 12 differentially 
regulated genes in the “stromal metagene,” BEV 
downregulated all genes except COL5A1 and COL5A2 
(Fig. 3A). Of the six differentially regulated genes in 
T-cell metagene, BEV reduced the expression levels of 
all five genes except SELL, while genes in MHC1 
metagene were upregulated particularly in response 
to LT treatment. Among the VEGF metagene, the ex-
pression levels of NDRG1 and ANGPTL4 were re-
duced in both ST and LT, but levels of ADM were 
increased in response to LT treatment. Most of the 
genes in VEGF metagene were regulated by HIF1A 
gene. However, we did not observe upregulation of 
hypoxia markers except ADM. Analyzing the hypoxia 
metagene [24], we further confirmed that the genes in 
hypoxia metagene exhibited low expression in re-
sponse to both ST and LT of BEV except ADM in 
VEGF-driven model (Fig. 3C). Among the other met-
agenes, it was notable that IL8 was gradually in-
creased in response to BEV treatment, more signifi-
cantly in the LT treatment (Fig. 3A).  
In contrast to MV165 xenograft tumors, genes 
within the stromal metagene, T-cell and VEGF meta-
genes in ML20 were significantly upregulated in re-
sponse to BEV treatment at both short and long 
treatment to BEV (Fig. 3B). On the other hand, genes 
in MHC1 metagene were downregulated, which was 
the opposite response when compared with MV165. 
Another distinct observation was that some of the 
hypoxia genes, including CA9, SLC16A1, NDGR1, and 
GAPDH, were upregulated in ML20, suggesting that 
BEV induces hypoxia markers in the non-VEGF mod-
el in contrast to MV165 (Fig. 3D). 
BEV treatment and altered intrinsic subtypes 
in VEGF-driven tumors 
Using DNA microarrays, Perou et al [25, 26] and 
Sorlie et al [27] classified breast carcinomas into five 
molecular subtypes: ER-positive (luminal A), 
ER-positive (luminal B), ER-negative/HER2-enriched, 
basal-type, and normal-like subtypes. A 50-gene sub-
type predictor assay (PAM50) has been developed 
representing each intrinsic subtype of breast cancer 
[28]. We analyzed the expression levels of the PAM50 
genes in microarray analysis of MV165 samples.  
Thirty-six of these 50 genes showed differential regu-
lation in response to ST and/or LT treatment to BEV 
compared with vehicle (Fig. 4A).  
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Figure 4. Effect of bevacizumab on intrinsic subtypes in ML20 and 
MV165 xenograft tumors; Heatmap representation of differentially 
regulated genes in comparison to PAM50 genes A, MV165-ST 
(short-term) and MV165-LT (long term) normalized to vehicle, B, 
ML20-ST and ML20-LT normalized to vehicle, C, Quantitative real-time 
RT-PCR validation of ESR1, KRT5 (cytokeratin 5), and KRT4 (cytokeratin 
14). Fold change for each comparison was calculated using DataAssist 
Software (Applied Biosystems). Data is normalized of a reference gene 
(ACTB). *P<0.05 statistically significant. 
 
 
As expected, most of the genes repre-
sentative of low proliferation in luminal A 
(BIRC5, CENPF, PTTG1) were downregulated 
in response to BEV irrespective of the treat-
ment period. Furthermore, a shift to luminal 
B from luminal A after development of re-
sistance to BEV treatment was not observed. 
Markers in luminal B, such as BCL2 and 
MKI67, were decreased in both ST and LT 
treatment. However, few genes were elevat-
ed, such as CDH3, KRT14 (CK14), and KRT5 
(CK5), in response to BEV. The upregulation 
of basal-like cytokeratins (CK5/6 and CK14) 
was confirmed by comparison of PAM50 
genes. In contrast, ESR1 (estrogen receptor 
alpha) is downregulated in both ST and LT 
BEV treatments. 
We next examined the expression levels 
of PAM50 genes in ML20 microarray sets. As 
in MV165 model, 36 of these 50 genes showed 
differential regulation in response to ST 
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and/or LT treatment to BEV compared with vehicle 
(Fig. 4B). However, a distinct set of genes were dif-
ferentially regulated in ML20 compared with MV165 
groups. The genes upregulated showed a more com-
plex gene expression profiling including BIRC5, 
PHGDH, CDC6, SFRP1, and FGFR4. ESR1, KRT5, and 
KRT14 were downregulated in this set. In general, 
BEV treatment showed a more complex gene expres-
sion profiling in comparison to intrinsic subtypes. 
To further validate the effect of BEV on intrinsic 
subtypes, we performed qRT-PCR using the repre-
sentative genes for luminal A and myoepithelial gene 
sets (ESR1, KRT5, and KRT14) (Fig. 4C). ESR1 showed 
a significant decrease in both sensitive and resistant 
group compared with the vehicle of VEGF-driven 
tumor (P<0.05). On the other hand, KRT5 (CK5) levels 
were increased significantly in both sensitive 
(3.02-fold; P<0.05) and resistant (4.14-fold; P<0.05) 
groups, while KRT14 showed a 3.12-fold increase 
(P<0.05) in sensitive and a 3.33-fold increase in re-
sistant group compared with the vehicle group. These 
results suggest that BEV treatment may contribute to 
a switch of tumor cells with luminal characteristics to 
a myoepithelial, basal-like phenotype independent of 
treatment duration. 
In non-VEGF ML20, downregulation of ESR1 
was not significant. In addition, KRT5 and KRT14 
were downregulated in both ST and LT treatments. 
KRT5 levels were significantly reduced in ST 
(–1.66-fold; P<0.05) and LT (–2.12-fold; P<0.05), while 
KRT14 downregulation was significant at the LT 
(–1.96-fold; P<0.05).  
Effect of BEV on intrinsic subtypes at the 
protein level 
 To further validate the altered representative 
genes of intrinsic subtypes (ESR1, KRT5, and KRT14) 
at the protein level, we next performed im-
munostaining for these genes. We confirmed the up-
regulation of KRT14 in BEV-resistant MV165 cells 
(P=0.02), whereas the ML20 (de novo resistance) 
model presented a significant decrease in KRT14 
which confirmed the observations at the mRNA level 
(P=0.047) (Fig. 5A). We did not observe expression 
changes at the significant level for other genes (KRT5 
and ESR1) at the protein level (data not shown).  
To determine the proliferative effect of BEV on 
ML20 as observed by the PAM50 analysis, we as-
sessed the immunostaining for Ki67, the most widely 
used proliferation marker in breast tumor samples 
[29]. As expected, Ki67 expression was higher in 
ML20-ST tumors compared with ML20-V being sta-
tistically significant (P=0.044) (Fig. 5B). The Ki67 ex-
pression was lowered with the longer treatment of 
BEV [ML20-LT; P=0.044)]. These results suggest the 
distinct effect of BEV in the presence or absence of 
VEGF overexpression.    
Gene expression analysis of 
tumor environment using 
mouse-specific arrays 
To determine additional 
mechanisms associated with 
tumor microenvironment (e.g., 
stroma, endothelial cells, and 
pericytes of mouse origin) in 
ML20 and MV165 xenografts, 
we performed mouse specific 
gene expression profiling 
(mouse WG-6 v2.0 Expression 
Beadchips, Illumina) using V-, 
ST-, and LT-treated tumors for 
MV165 and ML20 xenografts. 
We observed that a larger 
number of stromal mouse 
genes were significantly altered 
in BEV progression versus 
progression with human tumor 
genes in MV165 tumors (Addi-
tional File 1: Suppl. Figs. S3, 
S4). Of the 15,492 genes that 
were expressed above back-
ground, 58 and 417 genes were 
 
Figure 5. Validation of selected genes using immunohistochemistry. ML20 (non-VEGF) and MV165 (VEGF-expressing); 
*Mann–Whitney test P<0.05 statistically significant. LT, long-term; ST, short-term; V, vehicle. 
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differentially regulated between MV165-LT versus 
MV165-ST and MV165-LT versus MV165-V, respec-
tively (P≤0.001) (Additional File 1: Suppl. Fig. S3). 
Among the 58 genes in MV165-LT compared with 
MV165-ST, 35 genes were unique to LT BEV, sug-
gesting candidate genes for acquired resistance. In 
contrast, 294 genes were altered when BEV reduced 
the tumor growth significantly at 3 weeks. Among 
these 294 genes, 81 genes were unique to MV165-ST 
sensitive group. Table 2 illustrates the top differen-
tially regulated genes in MV165-LT and MV165-ST 
groups using mouse-specific arrays (P≤0.001). The top 
significant upregulated genes in resistant MV165-LT 
compared with sensitive MV165-ST were SLPI, 
GREM1, CCL21, CCL5 (RANTES), and CXCR6. 
Among the canonical pathways associated with these 
genes, most differentially regulated pathways were 
immune system–related signaling such as altered T 
cell and B cell signaling in rheumatoid arthritis, 
communication between innate and adaptive immune 
cells, and CCR5 signaling in macrophages. Other 
pathways included glucocorticoid receptor signaling, 
TGFB/BMP/hedgehog signaling, G-protein coupled 
receptor signaling, and AKT/mTOR/S6K signaling. 
Taken together, these results suggest that LT BEV 
treatment may alter the immune and the inflamma-
tory response that needs to be verified with other 
systems. ST treatment (MV165-ST versus MV165-V) 
suggests differential regulation of TGFB pathway 
members such as TGFB1. 
 We next compared ML20 tumors insensitive at 
the shorter treatment time with vehicle-treated tu-
mors using mouse-specific arrays. Of the 15,492 genes 
that were above background, 542 and 22 genes were 
differentially regulated in ML20-ST compared with 
ML20-V and ML20-ST compared with ML20-LT, re-
spectively (P≤0.001) (Additional File 1: Suppl. Fig. S4). 
Table 2 lists the top differentially regulated genes in 
ML20-ST and ML20-LT groups using mouse arrays 
(P≤0.001). The top significant downregulated genes in 
ML20-ST compared with ML20-V were SPP1, F2R, 
COL4A2, LGMN, and CTGF. No upregulated genes 
were present at P≤0.001. The top canonical pathways 
associated with these genes include the role of osteo-
blasts, osteoclasts and chondrocytes, clath-
rin-mediated endocytosis signaling/glioma inva-
siveness signaling and T cell regulation. Further 
comparison of ML20 tumors with LT treatment versus 
ST treatment have identified the germ cell–Sertoli cell 
junction signaling, glucocorticoid receptor signaling 
and immune response pathways among the top 
pathways. These results suggest that the nature of 
response and resistance is primarily altered based on 
the presence or absence of VEGF expression. 
Table 2. Top differentially-regulated genes in MV165 and ML20 in response to short-term (ST) and long-term (LT) bevacizumab 
treatment using mouse arrays 
Gene Symbol Canonical Pathway Gene Symbol Canonical Pathway 
MV165-LT versus MV165-ST ML20-LT versus ML20-ST 
SLPI Tumor angiogenesis/ glucocorticoid re-
ceptor signaling 
ACTG2 Germ cell–Sertoli cell junction signaling 
GREM1 
TGFB/BMP/hedgehog signaling SLPI Tumor angiogenesis/ glucocorticoid receptor 
signaling 
CCL21 
Altered T cell and B cell signaling in rheu-
matoid arthritis 
EGR1 Immune response pathways 
CCL5 (RANTES) 
Communication between innate and adap-
tive immune cells/ CCR5 signaling in 
macrophages/ glucocorticoid receptor 
signaling/ chemokine signaling 
BCKDK Glucocorticoid receptor signaling 
CXCR6 
G-protein coupled receptor signaling/ 
AKT/mTOR/S6K signaling 
ANKRD1 26S proteasome pathway 
MV165-LT versus MV165-V ML20-LT versus ML20-V 
CXCL14 
Dendritic cell maturation/glucose metabo-
lism MGP BMP pathway 
GREM1 
TGFB/BMP/hedgehog signaling 
SPP1 
Role of osteoblasts, osteoclasts and chondro-
cytes 
CD72 Systemic lupus erythematosus signaling B2M Regulation of immune response 
CD52 T cell activation LOX Lipoxygenase and  cyclooxygenase pathways 
LY6E 
Interferon signaling; systemic lupus ery-
thematosus signaling F2R 
Clathrin-mediated endocytosis signal-
ing/glioma invasiveness signaling 
MV165-ST versus MV165-V ML20-ST  versus ML20-V 
CD72 Systemic lupus erythematosus signaling SPP1 Role of osteoblasts, osteoclasts and chondro-
cytes 
CH25H Cholesterol and lipid metabolism F2R Clathrin-mediated endocytosis Signal-
ing/glioma invasiveness signaling 
TGFBI TGFB signaling COL4A2  
ESM1 Chemokine signaling LGMN T cell regulation 
COL4A1 Intrinsic Prothrombin activation pathway CTGF Hepatic fibrosis/hepatic stellate cell activa-
tion 
* ANOVA and Ingenuity Pathway Analysis have been performed; P value ≤0.005 
†Fold change ≥1.5 or ≤–1.5 
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Discussion  
Despite the initial promises, patients with breast 
cancer treated with BEV therapy have only a transi-
tory benefit. This might be attributed to the lack of 
identification of select groups of patients who might 
benefit from this drug. Furthermore, numerous po-
tential mechanisms may contribute to resistance to 
antiangiogenic agents including VEGF therapy (re-
viewed in Sledge et al [30]). It will be important to 
understand and overcome the underlying mecha-
nisms of resistance. Therefore, clinically relevant pre-
clinical models are critical to examine the potential 
mechanisms of antiangiogenic resistance at the mo-
lecular level. Novel targets identified in these models 
are potential candidates that need to be validated in 
clinical studies.  
MCF7 breast cancer xenografts overexpressing 
VEGF (MV165) have been shown to exhibit greater 
tumor growth and result in acquisition of metastatic 
capability into the lungs of the orthotopically im-
planted xenograft-bearing mice, while VEGF-lacking 
(ML20) breast cancer xenografts have a much slower 
growth rate and do not metastasize [16, 31].  ML20 
xenograft tumors that lack expression of VEGF exhib-
ited de novo resistance to BEV. In contrast, MV165 
cells were sensitive to BEV treatment. However, this 
effect was transitory, as the tumors grow back even 
after continuation of the therapy, indicating devel-
opment of acquired resistance. Given the fact that 
ML20 and MV165 differ by genetically overexpressed 
VEGF, this indicates that BEV may exert its an-
ti-tumor activity mainly through its actions on VEGF 
ligand and receptor pathway and the presence or ab-
sence of VEGF determines the nature of resistance, de 
novo or acquired, to BEV.   
Comparative analysis of human-specific and 
mouse-specific microarrays revealed that MV165 and 
ML20 xenograft tumors exhibited distinct gene pro-
files (Additional File 1: Suppl. Figs. S1–S4). Using 
human-specific arrays, the TGFB/BMP/hedgehog 
signaling was among the top significant genes in 
MV165 set. The expression levels of FST gene were 
inversely correlated with BEV sensitivity both in mi-
croarray and qRT-PCR analyses. FST, the antagonist 
of activin belonging to TGFB superfamily, acts as a 
pleiotropic growth factor system that controls cell 
proliferation, differentiation, and apoptosis in several 
models in an autocrine and paracrine fashion [32-34]. 
The role of FST is complex and tissue context de-
pendent. Krneta et al. found that FST-expressing tu-
mors were smaller in human R30C mammary carci-
noma model compared with activin-expressing tu-
mors [35]. In contrast, in our study, FST expression 
was associated with proliferation; inhibition of tumor 
growth was correlated with inhibition of FST levels.  
Upregulation of genes involved in NOTCH and 
WNT signaling was also observed in BEV resistant 
MV165 tumors. HEY2, a downstream effector of 
NOTCH signaling, was among the top significantly 
upregulated genes. Transcriptome profiling of normal 
human mammary subpopulation has revealed the 
expression of FST and NOTCH4 in the cluster con-
sisting of primitive bipotent colony-forming cells and 
differentiated myoepithelial cells, while expression of 
NOTCH3 was higher in the committed luminal pro-
genitor cells [22]. Among the NOTCH receptors, 
breast cancer stem cell activity was dependent signif-
icantly on NOTCH4 [36]. In addition, NOTCH signal-
ing has been reported to mediate the tumor resistance 
to BEV in xenografts of glioblastoma [37]. In the cur-
rent study, the expression levels of NOTCH4 gradu-
ally increased with BEV therapy and this increase was 
statistically significant in the LT therapy of MV165 
group, while the NOTCH3 expression remained sim-
ilar in response to the ST and LT treatment of BEV. 
Based on this information and our microarray data, 
the current study supports the evidence that upregu-
lation of FST and NOTCH4 may form the basis of an 
environment with cancer stem cell characteristics and 
confer resistance to anti-VEGF therapy in MV165 
xenograft model. Although less dramatic, FST and 
NOTCH4 levels are also increased in non-VEGF mod-
el. Therefore, targeting these pathways may present 
an important mechanism to prevent resistance to BEV. 
Further detailed studies will reveal the exact nature of 
the interaction between FST/BMP/TGFB and NOTCH 
signaling. However, the balance between 
BMP/hedgehog and WNT/FGF/NOTCH networks is 
important for the maintenance of homeostasis among 
stem and progenitor cells [38, 39]   
In order to get a more detailed perspective of the 
overall changes in gene expression, we analyzed the 
gene expression data using previously described 
metagenes. Comparison of gene profiling with meta-
genes revealed that BEV decreased proliferation, 
stromal, T cell, and VEGF-related genes in these 
metagenes, but upregulated the genes associated with 
myoepithelial/basal phenotype. However, BEV was 
not effective in decreasing the tumor growth in 
non-VEGF ML20 model and upregulated most of the 
genes, in particular metagenes related to the prolifer-
ation and tumor microenvironment (stromal, T cell, 
and VEGF metagenes), suggesting the importance of 
VEGF expression in altered response to BEV therapy, 
at least in the ST treatment. 
Hypoxic adaptation to BEV treatment is also 
observed in other experimental models [40]. Our data 
indicates that increased hypoxia is not a universal 
response to antiangiogenic treatment and this may 
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dictate the choice of synergistic agents. However, we 
observed an increase in markers (FST and NOTCH4) 
implicated with cancer stem cells. This finding is col-
laborated by a recent study which emphasized that 
anti-angiogenic agents increase breast cancer stem 
cells. Although these authors attribute the cancer stem 
cell phenotype to tumor hypoxia [41], as indicated in 
our study, other pathways may be involved.   
An important observation of our study was that 
BEV treatment of MV165 cells resulted in a change in 
the intrinsic subtype of tumors. BEV treatment re-
sulted in a shift of expression of the “intrinsic” genes 
(PAM50) within the tumor cells resulting in expres-
sion of genes associated with myoepithelial/ ba-
sal-like subtype. In congruence with this, there was 
downregulation of genes associated with luminal 
subtypes including ER. Retinoic acid receptor [42] 
pathway, which is associated with luminal differenti-
ation was downregulated in MV165 after BEV treat-
ment. Although markers of basal-like subtype are the 
subject of an ongoing debate, marker panels have 
been proposed to include genes that are characteristic 
of basal epithelial cells which include downregulation 
of ER and upregulation of one or more high molecular 
weight/basal keratins (KRT5/6, KRT14, and KRT17) 
and CDH3 (P-cadherin) [43]. We were able to confirm 
these intrinsic subtype changes using qRT-PCR 
methods, whereas KRT14 expression was confirmed 
using immunohistochemistry as well.  Our findings 
show that BEV treatment has the ability to switch the 
cells to a more aggressive basal-like phenotype. It is 
possible that this may eventually alter the response to 
BEV. Hence, these data may shed light on the transi-
tory effect of BEV observed in the E2100 first-line 
metastatic breast cancer trial [10], where an-
ti-VEGF-targeted therapy prolonged progression-free 
survival for a ST in metastatic breast cancer without 
improving overall survival. 
Using mouse specific-genes, we observed that a 
larger number of genes were significantly altered 
compared with human-specific genes in both models, 
supporting the effect of BEV on the pathways regu-
lating the tumor microenvironment. These results 
confirm the effect of BEV treatment on the tumor mi-
croenvironment as reported in an earlier study that 
analyzed mouse- and human-specific gene expression 
changes in BEV-resistant xenograft models of human 
lung adenocarcinoma [44]. In our model, the top 
mouse genes involved in acquired resistance in 
MV165 model (SLPI, CCL21, CCL5 (RANTES), and 
CXCR6) represent pathways associated with tumor 
angiogenesis, innate and adaptive immune system 
regulation and macrophage signaling. SLPI is over-
expressed in inflammatory breast cancer and has been 
shown to contribute to induction of inva-
sion-independent metastasis in mice mammary tu-
mors [45, 46]. Chemokines are well known to impact 
the tumor progression, either by promoting or inhib-
iting tumor growth and metastasis [47, 48]. CCL5 has 
been shown to play a role in breast metastatic pro-
cesses by increasing migration- and invasion-related 
properties [49]. CXCR6 and its ligand CXCL16 also 
contribute to the regulation of metastasis and invasion 
in cancer [50]. Both the proangiogenic signature and 
the mesenchymal phenotype have also been reported 
in recent studies using BEV-resistant preclinical 
models in head and neck squamous cell carcinoma 
and in glioblastoma, respectively [51, 52].  
  In conclusion, this study reports the multifacet-
ed response to BEV in experimental tumors depend-
ing on the levels of VEGF expression. These include 
upregulation of cellular pathways related to re-
sistance as well as a change in the “intrinsic” subtype 
and acquisition of cancer stem cell characteristics. The 
genomic analyses identify several candidate 
genes/pathways that could potentiate the actions of 
VEGF and prevent development of resistance. The 
findings might shed some light on why patients 
treated with BEV may show partial response as 
demonstrated by increased progression-free survival 
but do not have a better overall survival. Further-
more, our data underline stratification of patients 
based on VEGF expression and provide preclinical 
evidence to develop relevant druggable targets for 
combination regimens to anti-VEGF therapy in the 
clinic.  
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